RESUMEN
PURPOSE: Patients treated with direct oral anticoagulants (DOACs) frequently undergo interventional procedures requiring temporary discontinuation of anticoagulant therapy. Little is known about remaining peri-procedural exposure to rivaroxaban in real-world patients. METHODS: Fifty-six patients with rivaroxaban treatment and scheduled cardiac catheterization were included in this prospective, observational, and single-center study. Rivaroxaban concentrations were determined by LC-MS/MS and a chromogenic anti-Xa assay. Population pharmacokinetic modeling was carried out on LC-MS/MS concentration data using NONMEM software, and results were applied to Monte Carlo simulations to predict appropriate rivaroxaban discontinuation intervals. RESULTS: Rivaroxaban concentrations ranged from Asunto(s)
Cateterismo Cardíaco
, Inhibidores del Factor Xa/sangre
, Inhibidores del Factor Xa/farmacocinética
, Periodo Preoperatorio
, Rivaroxabán/sangre
, Rivaroxabán/farmacocinética
, Anciano
, Cromatografía Liquida
, Inhibidores del Factor Xa/efectos adversos
, Femenino
, Hemorragia/inducido químicamente
, Humanos
, Masculino
, Persona de Mediana Edad
, Modelos Biológicos
, Método de Montecarlo
, Dinámicas no Lineales
, Rivaroxabán/efectos adversos
, Espectrometría de Masas en Tándem